466 related articles for article (PubMed ID: 31189728)
1. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
3. p38
Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
[TBL] [Abstract][Full Text] [Related]
4. BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells.
Campbell AE; Oliva J; Yates MP; Zhong JW; Shadle SC; Snider L; Singh N; Tai S; Hiramuki Y; Tawil R; van der Maarel SM; Tapscott SJ; Sverdrup FM
Skelet Muscle; 2017 Sep; 7(1):16. PubMed ID: 28870238
[TBL] [Abstract][Full Text] [Related]
5. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
[TBL] [Abstract][Full Text] [Related]
6. DUX4 expression activates JNK and p38 MAP kinases in myoblasts.
Brennan CM; Hill AS; St Andre M; Li X; Madeti V; Breitkopf S; Garren S; Xue L; Gilbert T; Hadjipanayis A; Monetti M; Emerson CP; Moccia R; Owens J; Christoforou N
Dis Model Mech; 2022 Nov; 15(11):. PubMed ID: 36196640
[TBL] [Abstract][Full Text] [Related]
7. The FSHD atrophic myotube phenotype is caused by DUX4 expression.
Vanderplanck C; Ansseau E; Charron S; Stricwant N; Tassin A; Laoudj-Chenivesse D; Wilton SD; Coppée F; Belayew A
PLoS One; 2011; 6(10):e26820. PubMed ID: 22053214
[TBL] [Abstract][Full Text] [Related]
8. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
[TBL] [Abstract][Full Text] [Related]
10. Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy.
DeSimone AM; Leszyk J; Wagner K; Emerson CP
Sci Adv; 2019 Dec; 5(12):eaaw7099. PubMed ID: 31844661
[TBL] [Abstract][Full Text] [Related]
11. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
Tassin A; Laoudj-Chenivesse D; Vanderplanck C; Barro M; Charron S; Ansseau E; Chen YW; Mercier J; Coppée F; Belayew A
J Cell Mol Med; 2013 Jan; 17(1):76-89. PubMed ID: 23206257
[TBL] [Abstract][Full Text] [Related]
12. Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells.
Jagannathan S; Shadle SC; Resnick R; Snider L; Tawil RN; van der Maarel SM; Bradley RK; Tapscott SJ
Hum Mol Genet; 2016 Oct; 25(20):4419-4431. PubMed ID: 28171552
[TBL] [Abstract][Full Text] [Related]
13. Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy.
Moyle LA; Blanc E; Jaka O; Prueller J; Banerji CR; Tedesco FS; Harridge SD; Knight RD; Zammit PS
Elife; 2016 Nov; 5():. PubMed ID: 27841748
[TBL] [Abstract][Full Text] [Related]
14. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
15. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
16. Deciphering transcription dysregulation in FSH muscular dystrophy.
Ehrlich M; Lacey M
J Hum Genet; 2012 Aug; 57(8):477-84. PubMed ID: 22718021
[TBL] [Abstract][Full Text] [Related]
17. DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis.
Young JM; Whiddon JL; Yao Z; Kasinathan B; Snider L; Geng LN; Balog J; Tawil R; van der Maarel SM; Tapscott SJ
PLoS Genet; 2013 Nov; 9(11):e1003947. PubMed ID: 24278031
[TBL] [Abstract][Full Text] [Related]
18. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy.
Saad NY; Al-Kharsan M; Garwick-Coppens SE; Chermahini GA; Harper MA; Palo A; Boudreau RL; Harper SQ
Nat Commun; 2021 Dec; 12(1):7128. PubMed ID: 34880230
[TBL] [Abstract][Full Text] [Related]
19. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
[TBL] [Abstract][Full Text] [Related]
20. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Nguyen Q; Yokota T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
